Travere Therapeutics (TVTX) Competitors $21.15 +0.39 (+1.88%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$21.14 -0.01 (-0.07%) As of 05/2/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVTX vs. BBIO, TGTX, LEGN, SRPT, TLX, ADMA, BPMC, VRNA, NUVL, and AXSMShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include BridgeBio Pharma (BBIO), TG Therapeutics (TGTX), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), ADMA Biologics (ADMA), Blueprint Medicines (BPMC), Verona Pharma (VRNA), Nuvalent (NUVL), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Travere Therapeutics vs. BridgeBio Pharma TG Therapeutics Legend Biotech Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares ADMA Biologics Blueprint Medicines Verona Pharma Nuvalent Axsome Therapeutics Travere Therapeutics (NASDAQ:TVTX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership. Do analysts prefer TVTX or BBIO? Travere Therapeutics currently has a consensus target price of $31.79, indicating a potential upside of 50.29%. BridgeBio Pharma has a consensus target price of $57.09, indicating a potential upside of 48.02%. Given Travere Therapeutics' higher probable upside, analysts clearly believe Travere Therapeutics is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87BridgeBio Pharma 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Do institutionals and insiders believe in TVTX or BBIO? 99.8% of BridgeBio Pharma shares are held by institutional investors. 4.1% of Travere Therapeutics shares are held by company insiders. Comparatively, 24.7% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings and valuation, TVTX or BBIO? Travere Therapeutics has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$233.18M8.05-$111.40M-$4.10-5.16BridgeBio Pharma$221.90M33.00-$535.76M-$2.85-13.53 Does the media prefer TVTX or BBIO? In the previous week, BridgeBio Pharma had 15 more articles in the media than Travere Therapeutics. MarketBeat recorded 35 mentions for BridgeBio Pharma and 20 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.02 beat BridgeBio Pharma's score of 0.81 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 14 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, TVTX or BBIO? Travere Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Is TVTX or BBIO more profitable? Travere Therapeutics has a net margin of -137.90% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-137.90% -1,636.87% -55.95% BridgeBio Pharma -241.44%N/A -75.69% Does the MarketBeat Community favor TVTX or BBIO? BridgeBio Pharma received 87 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 72.47% of users gave BridgeBio Pharma an outperform vote while only 60.93% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformTravere TherapeuticsOutperform Votes9260.93% Underperform Votes5939.07% BridgeBio PharmaOutperform Votes17972.47% Underperform Votes6827.53% SummaryBridgeBio Pharma beats Travere Therapeutics on 10 of the 18 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVTX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.88B$6.85B$5.56B$8.03BDividend YieldN/A2.91%5.07%4.23%P/E Ratio-5.167.5022.7718.87Price / Sales8.05259.05405.67106.84Price / CashN/A65.8538.1834.62Price / Book7.926.566.794.34Net Income-$111.40M$143.63M$3.22B$248.06M7 Day Performance15.38%3.35%3.36%3.18%1 Month Performance27.72%10.29%6.91%8.28%1 Year Performance237.86%-3.67%16.16%5.04% Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVTXTravere Therapeutics2.9269 of 5 stars$21.15+1.9%$31.79+50.3%+237.9%$1.88B$233.18M-5.16460Earnings ReportAnalyst ForecastNews CoverageBBIOBridgeBio Pharma4.6199 of 5 stars$35.89-1.2%$53.00+47.7%+38.6%$6.81B$221.90M-12.59400Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageTGTXTG Therapeutics3.3343 of 5 stars$42.03+1.7%$40.67-3.2%+168.3%$6.67B$329.00M-420.26290Upcoming EarningsNews CoveragePositive NewsLEGNLegend Biotech2.7136 of 5 stars$34.70+1.2%$78.82+127.1%-27.0%$6.37B$627.24M-36.531,070Positive NewsSRPTSarepta Therapeutics4.7683 of 5 stars$61.51+1.8%$158.70+158.0%-52.5%$5.97B$1.90B49.21840Upcoming EarningsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.57-6.5%$22.00+25.2%N/A$5.94B$783.21M0.00N/AAnalyst RevisionNews CoverageGap DownHigh Trading VolumeADMAADMA Biologics1.4813 of 5 stars$24.51+12.1%$22.50-8.2%+245.4%$5.82B$426.45M87.54530Upcoming EarningsOptions VolumeNews CoverageGap UpHigh Trading VolumeBPMCBlueprint Medicines1.7643 of 5 stars$88.51+1.0%$124.53+40.7%-2.4%$5.66B$508.82M-81.95640Earnings ReportAnalyst ForecastNews CoverageVRNAVerona Pharma2.7496 of 5 stars$68.83+5.1%$78.50+14.0%+363.5%$5.56B$42.28M-35.8530Earnings ReportAnalyst ForecastInsider TradeShort Interest ↓Analyst RevisionNews CoveragePositive NewsNUVLNuvalent1.9376 of 5 stars$75.20+2.3%$115.50+53.6%+10.1%$5.38BN/A-21.6740Upcoming EarningsNews CoveragePositive NewsAXSMAxsome Therapeutics4.8478 of 5 stars$107.24+0.9%$169.80+58.3%+50.0%$5.23B$385.69M-17.90380Upcoming EarningsAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies BridgeBio Pharma Competitors TG Therapeutics Competitors Legend Biotech Competitors Sarepta Therapeutics Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors ADMA Biologics Competitors Blueprint Medicines Competitors Verona Pharma Competitors Nuvalent Competitors Axsome Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVTX) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TVTX Stock Free TVTX Stock Alerts